Ongoing 17 Jul 2022

SHERLOCK

Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation.

Enquire

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Lung

Study Phase

Trial Identifiers

Registration number: ACTRN12622000973718

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12622000973718

GenesisCare Location(s)

North Shore

Principal Investigator(s)

Dr Malinda Itchins

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

State *

Postcode *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone

By submitting you acknowledge we will use the information you are providing to contact you about your enquiry. For more information about how we handle your personal information, please refer to the GenesisCare Privacy Policy.

SHERLOCK

Trial overview

Thank you for submitting.

An unexpected error has occurred.

How can we help?

GenesisCare

Website policies

Contact us

Media & Social